A Randomized, Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced Non-Small-Cell Lung Adenocarcinoma

Trial Profile

A Randomized, Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced Non-Small-Cell Lung Adenocarcinoma

Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Docetaxel (Primary) ; Ganetespib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms GALAXY-2
  • Sponsors Synta Pharmaceuticals
  • Most Recent Events

    • 18 Aug 2016 This trial has been completed in Belgium as per European Clinical Trials Database record.
    • 04 Nov 2015 Planned End Date changed from 1 Mar 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 04 Nov 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top